Plasma total homocysteine: instigator or indicator of cardiovascular disease?
Author:
- 1 July 2008
- journal article
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 45 (4) , 345-348
Abstract
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in developed countries. However, traditional risk factors cannot fully account for this. In the last 20 years, there has been an explosion of interest in plasma total homocysteine (tHcy) as a potential modifiable risk factor for CVD. Recent meta-analyses of epidemiological studies support the concept that increased tHcy concentrations are associated with CVD. This has led to the ‘homocysteine hypothesis’, which states that lowering plasma tHcy using folic acid and other B-vitamins will reduce the risk of CVD. In experimental studies, homocysteine has been shown to cause oxidative stress, endothelial cell dysfunction and promote thrombogenesis. However, data from recent large randomized controlled trials have shown that there is no clinical benefit to lowering plasma tHcy concentrations with folic acid and other B-vitamins. This lack of effect of tHcy lowering strongly suggests that homocysteine is not an instigator but merely an indicator of CVD.Keywords
This publication has 30 references indexed in Scilit:
- Effect of Folic Acid Supplementation on Risk of Cardiovascular DiseasesJAMA, 2006
- Homocysteine Lowering with Folic Acid and B Vitamins in Vascular DiseaseNew England Journal of Medicine, 2006
- Homocysteine Lowering and Cardiovascular Events after Acute Myocardial InfarctionNew England Journal of Medicine, 2006
- Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trialsAmerican Heart Journal, 2006
- Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trialsThe American Journal of Clinical Nutrition, 2005
- Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and DeathJAMA, 2004
- Underestimation of the Importance of Homocysteine as a Risk Factor for Cardiovascular Disease in Epidemiological StudiesEuropean Journal of Preventive Cardiology, 2001
- Serum Homocysteine and Risk of Coronary Heart Disease and Cerebrovascular Disease in Elderly MenArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Plasma Homocysteine and Coronary Heart Disease: Systematic Review of Published Epidemiological StudiesEuropean Journal of Preventive Cardiology, 1998
- A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular DiseaseJAMA, 1995